Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Peter M. Neupert, a director at Adaptive Biotechnologies Corp (NASDAQ:ADPT), recently made a significant financial move involving the company’s common stock. According to a recent SEC filing, Neupert sold 10,000 shares at a weighted-average price of $7.05, amounting to a total of $70,500. The sale price ranged between $7.03 and $7.07 per share, with the stock currently trading at $7.62. The company, now valued at $1.14 billion, has seen remarkable momentum with a 112% return over the past year.
Additionally, on the same day, Neupert exercised stock options to acquire 50,000 shares at $4.07 each, totaling $203,500. Following these transactions, Neupert holds 224,690 shares directly. According to InvestingPro, the company maintains strong liquidity with a current ratio of 2.89, though investors should note its volatile price movements. InvestingPro analysis reveals 8 additional key insights about ADPT’s financial health and market position.
These transactions provide a snapshot of Neupert’s current stake and trading activity in the company, which specializes in biological products. Based on InvestingPro’s Fair Value analysis, ADPT currently appears slightly undervalued in the market.
In other recent news, Adaptive Biotechnologies Corporation reported fourth-quarter revenue of $47.5 million, surpassing analyst expectations of $46.15 million. The company’s adjusted loss per share was $0.23, which was narrower than the anticipated $0.25 loss. The Minimal Residual Disease (MRD) business, contributing 85% of the quarterly revenue, saw a 31% year-over-year increase, reaching $40.1 million. However, revenue from the Immune Medicine segment declined by 51% to $7.3 million. For the upcoming year, Adaptive projects MRD revenue between $175 million and $185 million, with total operating expenses estimated at $340-$350 million and a cash burn of $60-$70 million.
In a related development, Scotiabank (TSX:BNS) analyst Sung Ji Nam increased the price target for Adaptive Biotechnologies to $12.00 from $10.00, maintaining a Sector Outperform rating. This adjustment was made following the company’s strong fiscal year-end performance and promising MRD revenue growth forecast of approximately 30% for 2025. The company’s strategic initiatives, including electronic medical record integrations and commercial partnerships, are expected to drive this growth. Additionally, Adaptive aims for MRD adjusted EBITDA profitability in the latter half of 2025 and cash flow breakeven in the first half of 2026. Scotiabank’s outlook reflects confidence in the company’s growth potential and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.